Main > ENDOCRINOLOGY > Diabetes. Treatment > Biguanide. SulfonylUrea. Combi. > BuFormin.Salt+Glibenclamide Tablet > Patent. > Claims > Claim 15: Controlled Release Tablet > a) Core, i) BuFormin or Salt; ii) > Glyburide; iii) PolyVinyl Pyrrolido > ne & iv) Na Lauryl Sulfate; b) > Optional Seal Coat; c) > SemiPermeable Membrane Coating > i) Cellulose Acetate; ii) > PolyEthylene Glycol; MW=380-420. > & iii) Plasticizer & d) Passageway > in (c) Claim 28:Absorption Enhancer > Select: Fatty Acid, Chelant Etc. > Claim 29: Capric Acid Etc. Claim 30 > : Chelant Select: Citric Acid Etc. > Claim 31: Absorption Enhancer: Bile > Salt. Claim 33: Flux Enhancer. > Claim 34: Flux Enhancer: NaCl; PEG > Claim 35: Flux Enhancer: > PolyEthylene Glycol; MW=380-420. > Claim 37: (c) has 2 Passageways > Patent Assignee
Patent Assignee's products
USA. A